Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1531 studies found for:    Blood Coagulation Disorders: Clinical Trials
Show Display Options
RSS Create an RSS feed from your search for:
Blood Coagulation Disorders: Clinical Trials
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  "Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Conditions: Myocardial Ischemia;   Blood Coagulation Disorders;   Coronary Artery Disease;   Heart Valve Diseases
Intervention: Drug: Recombinant Activated Factor VII
2 Active, not recruiting A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
3 Completed Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: 40K PEG-rFIX
4 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
5 Completed Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: activated recombinant human factor VII;   Drug: vatreptacog alfa (activated)
6 Recruiting Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)
Conditions: Trauma;   Injury;   Bleeding;   Haemorrhage;   Coagulopathy
Interventions: Drug: Fibrinogen concentrate;   Drug: Placebo Comparator
7 Completed Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
8 Completed Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
9 Completed Hemodilution and Coagulopathy With 3 Colloids
Condition: Dilutional Coagulopathy
Intervention: Other: Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)
10 Unknown  Study Using Plasma for Patients Requiring Emergency Surgery
Conditions: Hemorrhagic Shock;   Blood Coagulation Disorders;   Blood Products;   Trauma;   Ruptured AAA
Intervention: Drug: Human Plasma
11 Completed Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
12 Active, not recruiting Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
13 Unknown  RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma
Condition: Major Trauma
Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate;   Drug: Fresh Frozen Plasma blood type 0, A, B and AB
14 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
15 Completed Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency;   Healthy
Interventions: Drug: catridecacog;   Drug: recombinant factor XIII
16 Completed Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII, long acting
17 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
18 Active, not recruiting Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
19 Completed
Has Results
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
20 Completed Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years